Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine.
作者信息
Ailani Jessica, Blumenfeld Andrew M
机构信息
Department of Neurology, MedStar Georgetown University Hospital, Washington, District of Columbia, USA.
The Neurology Center, Headache Center of Southern California, Carlsbad, California, USA.
出版信息
Headache. 2022 Jan;62(1):106-108. doi: 10.1111/head.14244. Epub 2021 Dec 7.
Abstract
摘要
相似文献
1
Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine.降钙素基因相关肽（CGRP）单克隆抗体与A型肉毒毒素联合治疗慢性偏头痛的预防性治疗
Headache. 2022 Jan;62(1):106-108. doi: 10.1111/head.14244. Epub 2021 Dec 7.
2
The introduction of the CGRP monoclonal antibodies and their effect on the prescription patterns of chronic migraine preventive medications in a tertiary headache center: A retrospective, observational analysis.CGRP 单克隆抗体的引入及其对三级头痛中心慢性偏头痛预防药物处方模式的影响：一项回顾性观察分析。
Headache. 2024 Feb;64(2):188-194. doi: 10.1111/head.14642. Epub 2023 Oct 26.
3
An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine.一项关于唾液降钙素基因相关肽水平与慢性偏头痛急性干预和预防性使用肉毒毒素 A 治疗关系的探索性研究。
Headache. 2014 Feb;54(2):269-77. doi: 10.1111/head.12250. Epub 2013 Oct 22.
4
Partial and nonresponders to onabotulinumtoxinA can benefit from anti-CGRP monoclonal antibodies preventive treatment: A real-world evidence study.对肉毒杆菌毒素 A 部分和无应答者可以从抗降钙素基因相关肽单克隆抗体预防性治疗中获益：一项真实世界证据研究。
Eur J Neurol. 2021 Jul;28(7):2378-2382. doi: 10.1111/ene.14828. Epub 2021 Apr 5.
5
Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis.偏头痛预防用抗 CGRP 单克隆抗体：系统评价及获益或危害分析。
Cephalalgia. 2021 Jun;41(7):851-864. doi: 10.1177/0333102421989601. Epub 2021 Feb 10.
6
Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine.真实世界证据的汇总分析支持在慢性偏头痛中联合使用抗 CGRP mAbs 和肉毒毒素 A
Toxins (Basel). 2022 Aug 1;14(8):529. doi: 10.3390/toxins14080529.
7
Botulinum Toxin in the Treatment of Headache.肉毒毒素在头痛治疗中的应用。
Toxins (Basel). 2020 Dec 17;12(12):803. doi: 10.3390/toxins12120803.
8
Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?抗 CGRP 单克隆抗体与肉毒毒素联合预防偏头痛：是否合理？
Headache. 2020 Jun;60(6):1056-1065. doi: 10.1111/head.13843. Epub 2020 May 21.
9
2022 Taiwan Guidelines for Preventive Treatment of Migraine.2022 年台湾偏头痛预防性治疗指南。
Acta Neurol Taiwan. 2022 Sep 30;31(3):164-202.
10
Efficacy and Tolerability of Calcitonin Gene-Related Peptide-Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine.降钙素基因相关肽靶向单克隆抗体药物作为依替巴肽治疗慢性偏头痛患者的附加疗法的疗效和耐受性。
Pain Med. 2021 Aug 6;22(8):1857-1863. doi: 10.1093/pm/pnab093.
引用本文的文献
1
Neuroinflammatory crosstalk in migraine: consolidated activity of rizatriptan and meloxicam in suppressing CGRP-induced nociception and COX-mediated inflammation.偏头痛中的神经炎症相互作用：利扎曲普坦与美洛昔康在抑制降钙素基因相关肽诱导的伤害感受和环氧化酶介导的炎症方面的联合作用
Inflammopharmacology. 2025 Jul 16. doi: 10.1007/s10787-025-01848-1.
2
Calcitonin gene-related peptide-targeted therapies for migraine.降钙素基因相关肽靶向治疗偏头痛
Aust Prescr. 2025 Apr;48(2):40-46. doi: 10.18773/austprescr.2025.017.
3
Real-World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review.阿托格潘与肉毒杆菌毒素A联合用于慢性偏头痛预防性治疗的安全性和有效性的真实世界证据：一项回顾性病历审查。
Pain Ther. 2024 Dec;13(6):1571-1587. doi: 10.1007/s40122-024-00649-8. Epub 2024 Sep 17.
4
Combination of anti-CGRP/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: a retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establish the efficacy and safety.抗降钙素基因相关肽/降钙素基因相关肽受体单克隆抗体与A型肉毒毒素联合应用作为难治性慢性偏头痛的一种新型治疗方法：真实世界临床证据的回顾性研究及一项双盲、随机临床试验方案以确定其疗效和安全性
Front Pharmacol. 2023 Dec 13;14:1296577. doi: 10.3389/fphar.2023.1296577. eCollection 2023.
5
Efficacy and Safety of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Preventing Migraines: A Systematic Review.抗降钙素基因相关肽（CGRP）单克隆抗体预防偏头痛的疗效与安全性：一项系统评价
Cureus. 2023 Sep 19;15(9):e45560. doi: 10.7759/cureus.45560. eCollection 2023 Sep.
6
An Update on Temporomandibular Disorders (TMDs) and Headache.颞下颌关节紊乱病（TMDs）与头痛的最新进展
Curr Neurol Neurosci Rep. 2023 Oct;23(10):561-570. doi: 10.1007/s11910-023-01291-1. Epub 2023 Aug 15.
7
Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review.多模式偏头痛管理与对偏头痛缓解的追求：一项叙述性综述
Neurol Ther. 2023 Oct;12(5):1533-1551. doi: 10.1007/s40120-023-00529-x. Epub 2023 Aug 5.
8
Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study.Ubrogepant 联合肉毒毒素 A 治疗偏头痛的真实世界疗效、满意度和优化：来自 COURAGE 研究的结果。
J Headache Pain. 2023 Aug 3;24(1):102. doi: 10.1186/s10194-023-01622-0.
9
Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review.阻断降钙素基因相关肽通路的单克隆抗体治疗偏头痛预防的 10 个开放性问题：叙述性综述。
J Headache Pain. 2023 Aug 1;24(1):99. doi: 10.1186/s10194-023-01637-7.
10
Safety of Onabotulinumtoxin A in Chronic Migraine: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.肉毒毒素 A 在慢性偏头痛中的安全性：随机临床试验的系统评价和荟萃分析。
Toxins (Basel). 2023 May 12;15(5):332. doi: 10.3390/toxins15050332.
本文引用的文献
1
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.美国头痛学会共识声明：更新将新的偏头痛治疗方法整合到临床实践中的建议。
Headache. 2021 Jul;61(7):1021-1039. doi: 10.1111/head.14153. Epub 2021 Jun 23.
2
Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?抗 CGRP 单克隆抗体与肉毒毒素联合预防偏头痛：是否合理？
Headache. 2020 Jun;60(6):1056-1065. doi: 10.1111/head.13843. Epub 2020 May 21.
3
FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.前瞻性研究：评估肉毒毒素 A 与托吡酯预防成人慢性偏头痛的比较效果。
Headache. 2019 Nov;59(10):1700-1713. doi: 10.1111/head.13653. Epub 2019 Sep 26.
4
Exploring the effects of extracranial injections of botulinum toxin type A on prolonged intracranial meningeal nociceptors responses to cortical spreading depression in female rats.探讨 A 型肉毒毒素颅外注射对雌性大鼠皮质扩散性抑制引起的延髓脑膜伤害感受器反应的影响。
Cephalalgia. 2019 Oct;39(11):1358-1365. doi: 10.1177/0333102419873675. Epub 2019 Aug 31.
5
The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice.美国头痛学会关于将新的偏头痛治疗方法纳入临床实践的立场声明。
Headache. 2019 Jan;59(1):1-18. doi: 10.1111/head.13456. Epub 2018 Dec 10.
6
Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal Nociceptors.孚来美单抗——一种人源化抗降钙素基因相关肽单克隆抗体——抑制薄髓鞘（Aδ）而非无髓鞘（C）的脑膜伤害感受器。
J Neurosci. 2017 Nov 1;37(44):10587-10596. doi: 10.1523/JNEUROSCI.2211-17.2017. Epub 2017 Sep 29.
7
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.依瑞奈玛单抗预防慢性偏头痛的安全性和疗效：一项随机、双盲、安慰剂对照的 2 期临床试验。
Lancet Neurol. 2017 Jun;16(6):425-434. doi: 10.1016/S1474-4422(17)30083-2. Epub 2017 Apr 28.
Zotero 插件